Scientists investigate how immune cells influence breast cancer treatment

NCT ID NCT04022616

Recruiting now Knowledge-focused Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects blood and tumor samples from 99 breast cancer patients to examine how certain immune cells (myeloid-derived suppressor cells) affect the function of natural killer cells. The goal is to understand immune system interactions and potentially predict chemotherapy responses. Participants must be 18 or older with stage I-III breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors predict which breast cancer patients will respond to chemotherapy based on immune cell levels.
What could go wrong: This is an early observational study, not a treatment trial. It may not lead to any direct benefit for participants or change current care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.